The relationship between yerba mate consumption and cardiovascular health has been studied primarily through observational studies and animal models — research designs that can identify associations but cannot establish causation. A randomized, controlled, blind, crossover trial scheduled for publication in August 2025, authored by Bravo L. and colleagues, addresses this methodological gap by testing the cardiometabolic effects of moderate yerba mate intake in subjects with no prior history of regular consumption — eliminating the confounding influence of long-term dietary habits.
Trial Design: Gold-Standard Methodology
The trial enrolled both normocholesterolemic (healthy) and hypercholesterolemic subjects — the latter defined by elevated LDL cholesterol — and employed a crossover design in which each participant served as their own control. Participants consumed three servings of yerba mate tea daily for eight weeks during the intervention phase, followed by a washout period, and then an equivalent placebo phase (or vice versa, randomized). The blind design ensured that neither participants nor outcome assessors knew which phase was active. Measured endpoints included blood pressure, blood lipids (total cholesterol, LDL-C, HDL-C, triglycerides), fasting glucose, body composition, and a panel of inflammatory biomarkers including cytokines and chemokines.
Results: Across-the-Board Cardiovascular Benefits
After eight weeks of daily mate consumption, participants showed significant reductions in both systolic and diastolic blood pressure. The effect was observed in both the healthy and hypercholesterolemic groups, with the hypercholesterolemic cohort showing a more pronounced reduction in diastolic blood pressure. LDL cholesterol decreased significantly in normocholesterolemic individuals — a finding the authors describe as noteworthy because it suggests that mate may exert lipid-lowering effects even in subjects with initially healthy lipid profiles.
Inflammatory and Hormonal Modulation
Beyond hemodynamic and lipid changes, the trial documented significant decreases in pro-inflammatory cytokines and chemokines — molecular signals that drive chronic low-grade inflammation, a recognized precursor to atherosclerosis and metabolic syndrome. Additionally, the researchers observed a reduction in ghrelin (the 'hunger hormone') and glucose-dependent insulinotropic polypeptide (GIP) — findings that align with separate research suggesting yerba mate may selectively upregulate GLP-1 while suppressing GIP, a hormonal profile associated with improved metabolic balance and reduced appetite.
Clinical Significance
The study's crossover design and blind methodology represent the highest level of evidence achievable in dietary intervention research. The authors conclude that yerba mate consumption 'could exert cardiometabolic protective effects,' including decreased blood pressure, improved blood lipid profiles, reduced inflammatory burden, and favorable body composition changes. They note that the effects were observed with moderate consumption (three servings daily) over a relatively short period (eight weeks), suggesting that longer-term consumption might produce more substantial benefits — a hypothesis that remains to be tested in extended trials.